32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that it will officially launch its $40 ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Distinguished professor leaves Switzerland to take up role in China, attracted by its reputation for cutting-edge biomedical ...

COVID-19 mRNA vaccines stimulated mucosal immunity in people previously infected with SARS-CoV-2, but generated only a tiny amount of immunity in people who had never been infected, according to a ...

In a recent study published in Nature Immunology, a team of researchers from the United States used non-human primate models to compare the protection conferred by an intramuscular booster dose of the ...

The relationship between inflammation and cancer represents one of the central paradoxes in modern tumor immunology. On one hand, chronic inflammation is a ...